ESTRO 2025 - Abstract Book

S1129

Clinical – Head & neck

ESTRO 2025

the best prognostic capacity in patients with HNC treated with chemo-Radiotherapy (CRT) and bio-Radiotherapy (BRT).

Material/Methods: Retrospective study of 345 patients with HNC diagnosed between 2000-2019. The different hematological parameters analyzed were obtained from a blood test at an interval of 4 weeks before to start of treatment. The disease specific survival (DSS) was the dependent variable. The relationship between host index and DSS was analyzed using a recursive partition analysis. Results: Patients treated with CRT (82.3%) BRT (17.7%). Tumor located in larynx (24.3%) , oral cavity (2.9%), oropharynx (57.7%), hypopharynx (15.1%). Of all the parameters and indices analyzed, the one with the best prognostic capacity was the "host index"(HI) before treatment, which combines the predictive capacity of hemoglobin and albumin concentrations,and the absolute value of neutrophils, monocytes and lymphocytes. Based on a recursive partition analysis, 3 groups of patients were defined based on the HI. Considering as the reference category patients with a HI less than 1.88 (n=80, 25.9%),patients with a value 1.88-3.62 (n=115, 37.2%) had a 2.74 times higher risk of dying as consequence of the tumor(95% CI: 1.41-5.30, P=0.003), and patients with a value greater than 3.62 (n=114, 36.9%) have a 5.62 times higher risk (95% CI: 2.95-10.81, P= 0.0001) Figure 1

Conclusion: The index derived from a peripheral blood analysis that had the best prognostic capacity in patients with HNSCC treated with chemo/bio radiotherapy was the host index.

Keywords: Host index, prognostic capacity, Head and neck

References: 1. Valero C, Zanoni DK, Pillai A, Ganly I, Morris LGT, Shah JP, et al. Host Factors independently associated with prognosis in patients with oral cavity cancer. JAMA Otolaryngol Head Neck Surg. 2020;146:699-707. doi: 10.1001/jamaoto.2020.1019. 2. Sansa A, Valero C, Holgado A, Vásquez R, Quer M, Patel SG, et al. External validation of the H-index (host index) in patients with head and neck squamous cell carcinomas. Head Neck. 2023;45:178-86. doi: 10.1002/hed.27224